Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation
Abstract
:1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Disclosure
Abbreviations
UTUC | Upper Tract Urothelial Carcinoma |
UC | Urothelial Carcinoma |
BC | Bladder Cancer |
KPP | Kidney Preserving Procedures |
PFS | Progression free survival |
fURS | Flexible Ureteroscopy |
Ho:YAG | Holmium:YAG |
References
- Soria, F.; Shariat, S.F.; Lerner, S.P.; Fritsche, H.-M.; Rink, M.; Kassouf, W.; Spiess, P.E.; Lotan, Y.; Ye, D.; Fernandez, M.I.; et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J. Urol. 2016, 35, 379–387. [Google Scholar] [CrossRef]
- Olgac, S.; Mazumdar, M.; Dalbagni, G.; Reuter, V.E. Urothelial Carcinoma of the Renal Pelvis: A clinicopathologic study of 130 cases. Am. J. Surg. Pathol. 2004, 28, 1545–1552. [Google Scholar] [CrossRef] [PubMed]
- Hall, M.; Womack, S.; Sagalowsky, A.I.; Carmody, T.; Erickstad, M.D.; Roehrborn, C.G. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients. Urology 1998, 52, 594–601. [Google Scholar] [CrossRef]
- Elawdy, M.M.; Osman, Y.; Taha, D.E.; El-Halwagy, S.; El-Hamid, M.A.; Abouelkheir, R.T. Long-term outcomes of upper tract urothelial carcinoma: A retrospective evaluation of single-center experience in 275 patients. Turk. J. Urol. 2019, 45, 177–182. [Google Scholar] [CrossRef]
- Rouprêt, M.; Babjuk, M.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E.M.; Cowan, N.C.; Dominguez-Escrig, J.L.; Gontero, P.; Mostafid, A.H.; et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur. Urol. 2020, 79, 62–79. [Google Scholar] [CrossRef] [PubMed]
- Hasan, M.N.; Rouprêt, M.; Keeley, F.; Cracco, C.; Jones, R.; Straub, M.; Traxer, O.; Osther, P.J.S.; Brehmer, M. Consultation on UTUC, Stockholm 2018 aspects of risk stratification: Long-term results and follow-up. World J. Urol. 2019, 37, 2289–2296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bianconi, M.; Cimadamore, A.; Faloppi, L.; Scartozzi, M.; Santoni, M.; López-Beltrán, A.; Cheng, L.; Scarpelli, M.; Montironi, R. Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. Ther. Adv. Urol. 2019, 11, 1756287218815372. [Google Scholar] [CrossRef]
- Mandalapu, R.S.; Remzi, M.; De Reijke, T.M.; Margulis, V.; Palou, J.; Kapoor, A.; Yossepowitch, O.; Coleman, J.; Traxer, O.; Anderson, J.K.; et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: Treatment of low-risk upper tract urothelial carcinoma. World J. Urol. 2016, 35, 355–365. [Google Scholar] [CrossRef] [Green Version]
- Fiuk, J.V.; Schwartz, B.F. Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management. World J. Nephrol. 2016, 5, 158–165. [Google Scholar] [CrossRef]
- Roupret, M.; Colin, P.; Yates, D.R. A new proposal to risk stratify urothelial carcinomas of the upper urinary tract (UTUCs) in a predefinitive treatment setting: Low-risk versus high-risk UTUCs. Eur. Urol. 2014, 66, 181–183. [Google Scholar] [CrossRef]
- Seisen, T.; Colin, P.; Rouprêt, M. Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat. Rev. Urol. 2015, 12, 155–166. [Google Scholar] [CrossRef]
- Rouprêt, M.; Hupertan, V.; Traxer, O.; Loison, G.; Chartier-Kastler, E.; Conort, P.; Bitker, M.-O.; Gattegno, B.; Richard, F.; Cussenot, O. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 2006, 67, 1181–1187. [Google Scholar] [CrossRef]
- Colin, P.; Rouprêt, M.; Ghoneim, T.P.; Traxer, O.; Zerbib, M.; Xylinas, E. Conservative Management of Upper Tract Urothelial Carcinoma in France: A 2004–2011 National Practice Report. Eur. Urol. 2013, 63, 405–406. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.L.; Bagley, D.H. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal con-tralateral kidneys. J. Urol. 2000, 164, 1173–1176. [Google Scholar] [CrossRef]
- Emiliani, E.; Talso, M.; Haddad, M.; Pouliquen, C.; Derman, J.; Côté, J.-F.; Doizi, S.; Millán, F.; Berthe, L.; Audouin, M.; et al. The True Ablation Effect of Holmium YAG Laser on Soft Tissue. J. Endourol. 2018, 32, 230–235. [Google Scholar] [CrossRef]
- Proietti, S.; Rodríguez-Socarrás, M.E.; Eisner, B.H.; Lucianò, R.; Martinez, M.J.B.; Yeow, Y.; Rapallo, I.; Saitta, G.; Scarfò, F.; Gaboardi, F.; et al. Thulium:YAG Versus Holmium:YAG Laser Effect on Upper Urinary Tract Soft Tissue: Evidence from an Ex Vivo Experimental Study. J. Endourol. 2021, 35, 544–551. [Google Scholar] [CrossRef]
- Doizi, S.; Germain, T.; Panthier, F.; Comperat, E.; Traxer, O.; Berthe, L. Comparison of Holmium:YAG and Thulium Fiber lasers on soft tissue: An ex vivo study. J. Endourol. 2021. [Google Scholar] [CrossRef]
- Rouprêt, M.; Babjuk, M.; Compérat, E.; Zigeuner, R.; Sylvester, R.J.; Burger, M.; Cowan, N.C.; Gontero, P.; Van Rhijn, B.W.; Mostafid, A.H.; et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur. Urol. 2018, 73, 111–122. [Google Scholar] [CrossRef]
- Roupręt, M.; Xylinas, E.; Colin, P.; Houédé, N.; Compérat, E.; Audenet, F.; Larré, S.; Masson-Lecomte, A.; Pignot, G.; Brunelle, S.; et al. Recommandations françaises du Comité de Cancérologie de l’AFU–Actualisation 2018–2020: Tumeurs de la voie excrétrice supérieure. Prog. Urol. 2018, 28, S32–S35. [Google Scholar] [CrossRef] [PubMed]
- Rouprêt, M.; Babjuk, M.; Compérat, E.; Zigeuner, R.; Sylvester, R.J.; Burger, M.; Cowan, N.C.; Böhle, A.; Van Rhijn, B.W.; Kaasinen, E.; et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur. Urol. 2015, 68, 868–879. [Google Scholar] [CrossRef]
- Rouprêt, M.; Babjuk, M.; Compérat, E.; Zigeuner, R.; Sylvester, R.; Burger, M.; Cowan, N.; Böhle, A.; Van Rhijn, B.W.; Kaasinen, E.; et al. European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. Eur. Urol. 2013, 63, 1059–1071. [Google Scholar] [CrossRef]
- Huusmann, S.; Wolters, M.; Kramer, M.W.; Bach, T.; Teichmann, H.O.; Eing, A.; Bardosi, S.; Herrmann, T.R. Tissue damage by laser radiation: An in vitro comparison between Tm: YAG and Ho: YAG laser on porcine kidney model. Singerplus 2016, 5, 266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taratkin, M.; Kovalenko, A.; Laukhtina, E.; Paramonova, N.; Spivak, L.; Wachtendorf, L.J.; Eminovic, S.; Afyouni, A.S.; Okhunov, Z.; Karagezyan, M.; et al. Ex vivo study of Ho:YAG and Thulium fiber lasers for soft tissue surgery: Wich laser for which case? Lasers Med. Sci. 2020, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Verges, D.P.; Lallas, C.D.; Hubosky, S.G.; Bagley, D.H. Endoscopic Treatment of Upper Tract Urothelial Carcinoma. Curr. Urol. Rep. 2017, 18, 31. [Google Scholar] [CrossRef] [PubMed]
- Azémar, M.-D.; Comperat, E.; Richard, F.; Cussenot, O.; Rouprêt, M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance. Urol. Oncol. Semin. Orig. Investig. 2011, 29, 130–136. [Google Scholar] [CrossRef] [PubMed]
- Margulis, V.; Shariat, S.F.; Matin, S.F.; Kamat, A.M.; Zigeuner, R.; Kikuchi, E.; Lotan, Y.; Weizer, A.; Raman, J.; Wood, C.G.; et al. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009, 115, 1224–1233. [Google Scholar] [CrossRef]
- Leow, J.J.; Orsola, A.; Chang, S.L.; Bellmunt, J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat. Rev. 2015, 41, 310–319. [Google Scholar] [CrossRef]
- Lughezzani, G.; Burger, M.; Margulis, V.; Matin, S.F.; Novara, G.; Roupret, M.; Shariat, S.F.; Wood, C.G.; Zigeuner, R. Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. Eur. Urol. 2012, 62, 100–114. [Google Scholar] [CrossRef]
- Seisen, T.; Peyronnet, B.; Dominguez-Escrig, J.L.; Bruins, H.M.; Yuan, C.Y.; Babjuk, M.; Böhle, A.; Burger, M.; Compérat, E.M.; Cowan, N.C.; et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur. Urol. 2016, 70, 1052–1068. [Google Scholar] [CrossRef]
- Yates, D.R.; Hupertan, V.; Colin, P.; Ouzzane, A.; Descazeaud, A.; Long, J.A.; Pignot, G.; Crouzet, S.; Rozet, F.; Neuzillet, Y.; et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: Proposal and multi-institutional validation of a post-operative nomogram. Br. J. Cancer 2012, 106, 1083–1088. [Google Scholar] [CrossRef]
- Cutress, M.L.; Stewart, G.D.; Wells-Cole, S.; Phipps, S.; Thomas, B.G.; Tolley, D.A. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. 2012, 110, 1608–1617. [Google Scholar] [CrossRef]
- Cornu, J.-N.; Rouprêt, M.; Carpentier, X.; Geavlete, B.; Medina, S.G.D.D.; Cussenot, O.; Traxer, O. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J. Urol. 2010, 28, 151–156. [Google Scholar] [CrossRef] [PubMed]
- Soderdahl, D.W.; Fabrizio, M.D.; Rahman, N.U.; Jarrett, T.W.; Bagley, D.H. Endoscopic treatment of upper tract transitional cell carcinoma. Urol. Oncol. Semin. Orig. Investig. 2005, 23, 114–122. [Google Scholar] [CrossRef] [PubMed]
- Pieras, E.; Frontera, G.; Ruiz, X.; Vicens, A.; Ozonas, M.; Pizá, P. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int. 2010, 106, 1319–1323. [Google Scholar] [CrossRef] [PubMed]
- Simone, G.; Papalia, R.; Loreto, A.; Leonardo, C.; Sentinelli, S.; Gallucci, M. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int. 2009, 103, 1052–1057. [Google Scholar] [CrossRef] [PubMed]
- Villa, L.; Haddad, M.; Capitanio, U.; Somani, B.; Cloutier, J.; Doizi, S.; Salonia, A.; Briganti, A.; Montorsi, F.; Traxer, O. Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution. J. Urol. 2017, 199, 66–73. [Google Scholar] [CrossRef]
- Scotland, K.B.; Kleinmann, N.; Cason, D.; Hubbard, L.; Tanimoto, R.; Healy, K.A.; Hubosky, S.G.; Bagley, D.H. Ureteroscopic Management of Large ≥2 cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience. Urology 2018, 121, 66–73. [Google Scholar] [CrossRef]
- Finch, W.; Johnston, R.; Shaida, N.; Winterbottom, A.; Wiseman, O. Measuring stone volume-three-dimensional software reconstruction or an ellipsoid algebra formula? BJU Int. 2014, 113, 610–614. [Google Scholar] [CrossRef]
- Panthier, F.; Doizi, S.; Illoul, L.; Berthe, L.; Traxer, O. Developing Free Three-dimensional Software for Surgical Planning for Kidney Stones: Volume is Better than Diameter. Eur. Urol. Focus 2020, 7, 589–590. [Google Scholar] [CrossRef] [PubMed]
- Mazzucchelli, R.; Scarpelli, M.; Galosi, A.B.; Di Primio, R.; Lopez-Beltran, A.; Cheng, L.; Montironi, R. Pathology of upper tract urothelial carcinoma with emphasis on staging. Int. J. Immunopathol. Pharmacol. 2014, 27, 509–516. [Google Scholar] [CrossRef]
- Aldoukhi, A.H.; Hall, T.L.; Ghani, K.R.; Maxwell, A.D.; MacConaghy, B.; Roberts, W.W. Caliceal Fluid Temperature During High-Power Holmium Laser Lithotripsy in an In Vivo Porcine Model. J. Endourol. 2018, 32, 724–729. [Google Scholar] [CrossRef] [PubMed]
- Musi, G.; Mistretta, F.A.; Marenghi, C.; Russo, A.; Catellani, M.; Nazzani, S.; Conti, A.; Luzzago, S.; Ferro, M.; Matei, D.V.; et al. Thulium Laser Treatment of Upper Urinary Tract Carcinoma: A Multi-Institutional Analysis of Surgical and Oncological Outcomes. J. Endourol. 2018, 32, 257–263. [Google Scholar] [CrossRef] [PubMed]
Group | Time (min) to Complete Ablation. Mean (SD) | Percentage of Non-Affected Tissue | Percentage of Ablated Necrotic Tissue with Recognizable Architecture | Percentage of Destroyed Unrecognized Tissue |
---|---|---|---|---|
1 (1 cm3) | 16.4 (2.7) | 0% | 0% | 100% |
2 (1.5 cm3) | 28.1 (2.5) | 0% | 0% | 100% |
3 (2 cm3) | 40.3 (3.3) | 0% | 0% | 100% |
4 (2.5 cm3) | 53.7 (4.3) | 0% | 8% | 92% |
5 (3 cm3) | 69.7 (6.6) | 0% | 15% | 85% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Barghouthy, Y.; Corrales, M.; Sierra, A.; Kamkoum, H.; Capretti, C.; Somani, B.; Compérat, E.; Traxer, O. Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation. Uro 2022, 2, 13-20. https://doi.org/10.3390/uro2010003
Barghouthy Y, Corrales M, Sierra A, Kamkoum H, Capretti C, Somani B, Compérat E, Traxer O. Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation. Uro. 2022; 2(1):13-20. https://doi.org/10.3390/uro2010003
Chicago/Turabian StyleBarghouthy, Yazeed, Mariela Corrales, Alba Sierra, Hatem Kamkoum, Camilla Capretti, Bhaskar Somani, Eva Compérat, and Olivier Traxer. 2022. "Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation" Uro 2, no. 1: 13-20. https://doi.org/10.3390/uro2010003
APA StyleBarghouthy, Y., Corrales, M., Sierra, A., Kamkoum, H., Capretti, C., Somani, B., Compérat, E., & Traxer, O. (2022). Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation. Uro, 2(1), 13-20. https://doi.org/10.3390/uro2010003